RYR3 and cancer: Similarly, the mutational status of RYR3 cannot stratify the survival in all cancer types (Fig. 9A), but can stratify the patient survival in ACC (P = 0.0071, Fig. 9B) and KIRC (P = 0.0042, Fig. 9E).